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Summary 49 
Background: Non-infectious uveitis represents a potentially sight-threatening ocular disorder as 50 
a result of chronic inflammation and its complications. Therapeutic success is limited by 51 
systemic adverse effects associated with long-term corticosteroid and immunomodulator use if 52 
topical medication is not sufficient to control the inflammation. This study assessed the efficacy and 53 
safety of adalimumab in systemic corticosteroid-dependent patients with inactive, non-infectious 54 
intermediate, posterior, or panuveitis. 55 
Methods: VISUAL II, a multinational, double-masked, phase 3 trial enrolled adult patients with 56 
inactive, non-infectious intermediate, posterior, or panuveitis requiring 10-35mg of prednisone 57 
daily to maintain inactivity. Patients were randomized 1:1 to receive adalimumab (loading dose, 58 
80mg; biweekly dose, 40mg) or placebo and were subjected to a mandatory prednisone taper 59 
from week 2. The primary efficacy endpoint time to treatment failure (TF) a multi-component 60 
endpoint, encompassing new active inflammatory chorioretinal and/or inflammatory retinal 61 
vascular lesions, anterior chamber cell grade, vitreous haze grade and visual acuity, as well as 62 
nine ranked secondary efficacy endpoints were assessed in the intent-to-treat population. 63 
Adverse event (AEs) rates were monitored. ClinicalTrials.gov, number-NCT01124838. 64 
Findings: 229 patients from 21 countries involving 62 study sites were enrolled. Patients 65 
receiving adalimumab were significantly less likely to have TF (hazard ratio=0·57; 95% CI, 66 
0·39-0·84; P=0·004). The 40th percentile for time to TF was 4·8 months for placebo and 10·2 67 
months for adalimumab group, respectively. Neither group reported opportunistic infections 68 
(excluding TB). No malignancies were reported in the placebo group while 1 (0.9%) 69 
adalimumab-treated patient reported non-serious squamous cell carcinoma of skin. The most 70 
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common AEs were arthralgia (Placebo: 12 [10·5%]; Adalimumab: 27 [23·5%), nasopharyngitis 71 
(Placebo: 16 [16·7%]; Adalimumab: 8 [15·7%], and headache (Placebo: 17 [14·9%]; 72 
Adalimumab: 17 [14·8%]).  73 
Interpretation: In systemic corticosteroid-dependent patients with inactive, non-infectious 74 
intermediate, posterior, or panuveitis adalimumab significantly lowered the risk for uveitic flare 75 
or visual acuity loss upon corticosteroid withdrawal. Based on the limited safety data, no new 76 
safety signals were observed. The rate of AEs was similar with adalimumab compared with 77 
placebo, although it is recognized that the study sample size does not allow complete conclusions 78 
on the safety of the therapy. 79 
. 80 
Funding: AbbVie,Inc.  81 
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Introduction 90 
Uveitis and its associated complications account for approximately 10-15% of preventable 91 
blindness in western countries.1-3 Corticosteroids (CS) have been the mainstay of uveitis 92 
treatment, but ocular and/or systemic adverse effects limit their long-term use in the treatment of 93 
intermediate, posterior, or panuveitis.4-6 The guidance from the Standardization of Uveitis 94 
Nomenclature (SUN) working group supports the use of systemic CS-sparing agents in patients 95 
on chronic CS treatment with quiescent disease; the ability to achieve a reduction in CS dose 96 
below a clinically meaningful threshold while maintaining inactive disease is a key determinant 97 
of treatment success.6   98 
There are few currently approved non-CS immunomodulatory agents for uveitis worldwide that 99 
can provide long-term control of uveitis7,8. Globally, there is an unmet need that warrants pursuit 100 
of additional effective therapies in steroid-dependent patients with non-infectious uveitis who are 101 
at risk for long-term CS side effects. 102 
Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine produced by various cells 103 
including macrophages and neutrophils.9-12 Adalimumab (Humira®; AbbVie Inc., North Chicago, 104 
IL) is a recombinant human immunoglobulin (IgG1) monoclonal antibody that binds specifically 105 
to TNF and neutralizes its biological function.13 Adalimumab’s safety and efficacy profile spans 106 
over 13 years for various approved inflammatory conditions such as rheumatoid arthritis, 107 
psoriasis, ankylosing spondylitis (AS), Crohn’s disease, ulcerative colitis, hidradenitis 108 
suppurativa and juvenile idiopathic arthritis (JIA).13 Several prospective studies, including the 109 
VISUAL I clinical trial, have shown the efficacy and safety of anti-TNF agents (infliximab and 110 
adalimumab) in the treatment of chronic and refractory uveitis and in reducing CS use. 14-19  111 
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There are two major therapeutic goals in uveitis: (1) To achieve quiescence in an eye with active 112 
intraocular inflammation, which was the focus of the VISUAL I trial. (2) To prevent a recurrence 113 
of intraocular inflammation, and reduce side effects of long-term CS usage in patients with a 114 
history of uveitic flare controlled by oral CS (≥10mg/d) treatment. The VISUAL II study was a 115 
randomized, double-masked, placebo-controlled clinical trial designed to assess the efficacy and 116 
safety of adalimumab in preventing reactivation of non-infectious intermediate, posterior, and 117 
panuveitis dependent on CS to maintain inactivity. 118 
Methods  119 
Study design and oversight 120 
VISUAL II was a phase 3, randomized, double-masked, placebo-controlled study conducted in 121 
21 countries involving 62 study sites between August 2010 and May 2015. The study protocol 122 
was approved by the responsible ethics committees and internal review boards and was 123 
performed in compliance with the Declaration of Helsinki, Good Clinical Practice (GCP) 124 
guidelines, and applicable local regulations.  125 
Study participants 126 
Eligible patients included individuals aged ≥18 years with inactive non-infectious intermediate, 127 
posterior, or panuveitis. Key inclusion criteria were inactive disease ≥28 days prior to the 128 
baseline visit and daily oral prednisone ≥10 to ≤35mg to maintain inactive uveitis. Inactive 129 
uveitis was defined as eyes without active inflammatory chorioretinal and/or retinal vascular 130 
lesions, anterior chamber (AC) cell grade ≤0·5+ (SUN, Working Group criteria; score range, 0– 131 
4+),20 and/or vitreous haze (VH) grade ≤0·5+ (National Eye Institute [NEI] criteria adapted by 132 
SUN).20,21 To demonstrate CS dependency, the patient should have a documented history of 133 
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experiencing at least 1 disease flare within 18 months of the screening visit. Additionally, this 134 
flare should have occurred during or up to a maximum of 28 days after tapering off the oral 135 
corticosteroid therapy.Patients were allowed only one ongoing immunosuppressive therapy (not 136 
including corticosteroids) within the last 28 days prior to the baseline visit. Additionally, the 137 
dose of the 1 concomitant immunosuppressive therapy allowed had to be stable for at least 28 138 
days prior to baseline and within the dose range as mentioned in Appendix, Table S1. Patient 139 
with corneal or lens opacity that precluded visualization of the fundus or that likely required 140 
cataract surgery during the duration of the trial were excluded. Patients with isolated anterior or 141 
infectious uveitis or any condition precluding safe participation in the study or interfering with 142 
study assessments were excluded (see appendix p.4 for complete inclusion and exclusion 143 
criteria). 144 
Randomisation and Masking 145 
At the baseline visit, patients were randomised to adalimumab or placebo treatment 146 
groups in a 1:1 ratio stratified by baseline immunosuppressant treatment with an interactive 147 
voice/web response system that assigned allocation numbers and treatments. Randomization was 148 
performed using a block size of 4. This was a double-masked study. All sponsor personnel with 149 
direct oversight of the conduct and management of the study (with the exception of those 150 
providing study treatments), investigators, study site personnel, and patients were masked to 151 
treatment. Masking was maintained throughout the 80-week treatment period.  152 
Procedures 153 
According to the treatment regimen, adalimumab and placebo were supplied in pre-filled 154 
syringes and were administered subcutaneously. The adalimumab group received an 80-mg 155 
baseline loading dose followed by 40-mg doses every other week starting at week 1 for the 156 
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duration of the study. Patients were on 10 to 35mg/d of oral prednisone at Baseline and from 157 
week 2, all patients underwent a mandatory prednisone taper to 0-mg by week 19. The schedule 158 
of study procedures is described (see appendix p.11). Presence or absence of inflammatory 159 
chorioretinal and/or retinal vascular lesions was determined by dilated indirect ophthalmoscopy. 160 
AC cell counts and cataracts were assessed using slit-lamp biomicroscopy at every study visit. 161 
The AC cell counts were graded according to SUN criteria while the cataracts were graded using 162 
Age-Related Eye Disease Study (AREDS) lens opacity grading system.20,22 VH was assessed 163 
using dilated indirect ophthalmoscopy and graded using SUN-adapted NEI criteria.20,21 ME was 164 
assessed using OCT (Stratus OCT [Carl Zeiss Meditec, Inc., Jena, Germany], Cirrus HD-OCT 165 
[Carl Zeiss Meditec, Inc.], or Spectralis [Heidelberg Engineering, Heidelberg, Germany]) (see 166 
appendix p.2). 167 
 168 
Outcomes 169 
Clinic visits were scheduled at screening; baseline; week 2, 4, and approximately every 4 weeks 170 
thereafter. Patients were assessed until treatment failure was determined or until completion of 171 
80 weeks of double-blind masked treatment. The maximum duration of treatment was 80 weeks 172 
or when the 106th treatment failure occurred. 173 
Beginning at or after week 2 and at every subsequent visit thereafter, treatment failure was 174 
determined if any of the following criteria were met in at least 1 eye: new active, inflammatory 175 
chorioretinal and/or inflammatory retinal vascular lesions (as determined by the investigator 176 
using clinical examination and/or ancillary testing such as fluorescein angiography); worsening 177 
of BCVA by ≥15 letters; 2-step increase in AC cell grade; 2-step increase in VH grade relative to 178 
Baseline. 179 
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The primary efficacy endpoint was time to treatment failure. Nine ranked secondary endpoints 180 
were tested in hierarchical order for statistical significance between adalimumab and placebo 181 
groups: (1) change in AC cell grade in each eye; (2) change in VH grade in each eye; (3) change 182 
in BCVA (logMAR) in each eye; (4) time to optical coherence tomography (OCT) evidence of 183 
macular edema (ME) in at least 1 eye; (5) percent change in central retinal thickness (CRT, i.e. 184 
CRT as defined by center point thickness for this analysis) in each eye; (6) change in NEI Visual 185 
Functioning Questionnaire-25 (VFQ-25) composite score; (7) change in VFQ-25 distance vision 186 
subscore; (8) change in VFQ-25 near vision subscore; and (9) change in VFQ-25 ocular pain 187 
subscore. All ranked secondary endpoints were analyzed comparing baseline with the final or 188 
early termination visit, except for endpoint 4. 189 
Adverse events (AEs) were monitored throughout the study and reported from the first dose of 190 
study drug until 70 days after the last dose of study drug or until patients were rolled into a 191 
separate extension study. Serious AEs were collected from the time of informed consent. AEs 192 
were tabulated using Medical Dictionary for Regulatory Activities (MedDRA) version 17·0 193 
system organ class and preferred terms. Adalimumab immunogenicity was evaluated at multiple 194 
time points throughout the study. 195 
Statistical analysis 196 
Sample size determination  197 
An overall treatment failure rate of 30% – 35% at 6 months is assumed with an expected 198 
treatment effect corresponding to an absolute difference of 15% between the treatment failure 199 
rates in the adalimumab and placebo group. A conservative assumption was that treatment 200 
failures would begin to occur after 2 months because of prednisone taper. A pooled dropout rate 201 
of 35% over 12 months was also assumed. Based on these assumptions, 84 to 107 treatment 202 
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failures were sufficient for a 2-sided significance level of 5% using a log-rank test. This 203 
calculation assumed power of 80% and an average accrual rate of 3 patients per month in the 204 
first 28 months and 16 patients per month thereafter.  205 
A series of calculations with different sample sizes using the event rate, recruitment rate, and 206 
dropout rate assumptions described above was performed using East5, v5·2·0·0 (Cytel Inc., 207 
Cambridge, MA). To achieve approximately 96 treatment failure events, it was determined that a 208 
sample size of approximately 220 patients was needed.  209 
An Independent data monitoring committee (IDMC) was set up at the beginning of the trial. The 210 
IDMC independently monitored and assessed data and was in effect until the end of the study. At 211 
each committee meeting, the IDMC undertook a comprehensive review and assessment of the 212 
cumulative safety data. The IDMC met approximately every 6 months or at a frequency 213 
determined by the IDMC to render their recommendation for either the termination or 214 
continuation of the study or an amendment to the study.  The IDMC analyses were conducted by 215 
a statistics vendor (Axio Research, LLC, Seattle, USA) external to AbbVie in order for AbbVie 216 
to remain masked to the results of the study. The IDMC met 8 times and did not identify safety 217 
issues requiring either a temporary hold or an early termination of the study. 218 
Protocol deviations were monitored via evaluation of inclusion/exclusion criteria at study entry 219 
and throughout the study. A total of 54 patients (23.9%) had important reportable deviations, 220 
including criteria violations, received excluded concomitant treatment, received wrong treatment 221 
or incorrect dose (adalimumab/placebo), received wrong treatment or incorrect dose 222 
(prednisone), and developed withdrawal criteria but was not withdrawn. No patients received a 223 
treatment to which they were not randomised for an entire period; therefore, all patients were 224 
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analyzed as randomised for both safety and efficacy analyses.  Baseline characteristics were 225 
summarized using descriptive statistics.  226 
Efficacy endpoints were analyzed in the intent-to-treat (ITT) data set (all patients randomized to 227 
treatment excluding 3 patients from 2 non-compliant sites). The primary endpoint “time to 228 
treatment failure” was compared between treatment groups using a log-rank test. A proportional 229 
hazards model with treatment as a factor was fitted to estimate the hazard ratio (HR) with its 230 
95% confidence interval. As additional exploratory endpoints, time to treatment failure due to 231 
each component of the primary endpoint was analyzed similarly.  232 
Testing of ranked secondary endpoints was conducted in hierarchical order and nominal P values 233 
for between-group differences were provided. Changes in AC cell grade, VH grade, BCVA, and 234 
CRT were compared between groups by analysis of variance with treatment as a factor adjusted 235 
for clustered observations within a patient, i.e. a repeated measures ANOVA was used to account 236 
for correlation between measurements from both eyes of a patient. CRT analysis used the OCT 237 
machine type as an additional factor. Time to OCT evidence of ME on or after week 2 was 238 
compared between groups with a log-rank test excluding patients with pre-existing ME at 239 
baseline. Changes in VFQ-25 composite score and sub-scores were compared between groups by 240 
analysis of variance with treatment as a factor. For analysis of secondary variables, with the 241 
exception of time to OCT evidence of ME, missing data were imputed using last observation 242 
carried forward.  243 
Safety analysis was performed on the safety set which included patients who received at least 244 
one dose of adalimumab. Treatment-emergent AEs were summarized descriptively by treatment 245 
group. AEs were presented as events per 100 patient-years (100PY) to avoid confounding by 246 
between-group differences in duration of exposure to study treatment. All statistical tests were 2-247 
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sided at a significance level of 0·05; analyses were performed by the study sponsor using SAS 248 
software (SAS Institute Inc., Cary, NC). This trial is registered with ClinicalTrials.gov, number 249 
NCT01124838. 250 
Role of Funding Source 251 
AbbVie funded the study, contributed to design, participated in the collection, analysis, and 252 
interpretation of the data, and in preparation and approval of this report. All authors had access to 253 
study data, reviewed and approved the final report, and take full responsibility for the accuracy 254 
of the data and statistical analysis. The corresponding author had full access to study data and 255 
had final responsibility for the decision to submit for publication. 256 
Results 257 
Patients 258 
The trial recruited 229 patients between August 10, 2010 and May 14, 2015; of these 229 259 
patients randomised to treatment, 226 were included in the ITT analyses (3 patients were 260 
excluded from 2 non-compliant sites) (placebo, n=111; adalimumab, n=115) (Figure 1). More 261 
patients were female (61%) and white (84%); 46% were diagnosed with panuveitis. Mean patient 262 
age was 42·5 years, and mean duration of uveitis was 61 months. There were no significant 263 
differences between randomised groups in demographics and baseline characteristics (Table 1). 264 
Fourteen patients receiving adalimumab and 16 patients receiving placebo discontinued the 265 
study. AEs were the most common cause of discontinuation in both groups (Figure 1). The 266 
median time of follow-up, measured as duration of treatment with study drug, for placebo and 267 
adalimumab groups was 155 and 245 days, respectively. 268 
Efficacy 269 
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An early and sustained separation of the treatment failure curves was observed between 270 
adalimumab and placebo groups. The 40th percentile for time to TF was 4·8 months for placebo 271 
and 10·2 months for adalimumab group, respectively, while median time to treatment failure was 272 
8·3 months for placebo and not estimable (>18 months) for adalimumab, as more than half of the 273 
adalimumab-treated patients did not experience treatment failure. The risk of treatment failure 274 
for patients in the adalimumab group was significantly reduced by 43% compared to patients in 275 
the placebo group (HR, 0·57; 95% CI, 0·39–0·84; P=0·004), (Figure 2A). Adalimumab treated 276 
patients had lower risk to fail and fewer criteria of treatment failure were met (Figure 3A). 277 
Nine ranked secondary variables were tested in hierarchical order for statistical significance 278 
between the adalimumab and placebo groups. Overall, the hierarchical testing procedure stopped 279 
after testing the first ranked secondary endpoint as no statistically significant difference was 280 
observed between the treatment groups; p-values provided for ranked secondary endpoints are 281 
exploratory in nature. Results were numerically in favor of adalimumab for all ranked secondary 282 
variables except change from baseline in VFQ-25 near vision subscore (Table 2).  283 
Exploratory analyses of the 4 pre-specified reasons for treatment failure were performed. The 284 
percentage of patients with treatment failure due to visual acuity showed the largest difference 285 
between the placebo and adalimumab groups (20·7% and 8·7%, respectively; Figure 3B). The 286 
risk of treatment failure based on visual acuity was reduced by 67% for patients in the 287 
adalimumab group compared to the placebo group (HR, 0·33; 95% CI, 0·16–0·70; P=0·002). 288 
The rates of treatment failure based on new active inflammatory chorioretinal and/or 289 
inflammatory retinal vascular lesions (HR, 0·55; 95% CI, 0·26–1·15; P=0·105), increase in AC 290 
cell grade (HR, 0·70; 95% CI, 0·42–1·18; P=0·180) and increase in VH grade (HR, 0·79; 95% 291 
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CI, 0·34–1·81; P=0·589; Figure 2B) were numerically lower in the adalimumab group 292 
compared with placebo.  293 
 294 
Safety 295 
The incidence of AEs was comparable between treatment groups (905 E/100PY and 879 296 
E/100PY placebo and adalimumab, respectively (Table 3). Serious AEs were reported at rates of 297 
14·1 E/100PY in the placebo group and 13·8 E/100PY in the adalimumab group. The most 298 
frequently reported AEs were injection site reactions (placebo, 22·6 E/100PY; adalimumab, 38·1 299 
E/100PY) and allergic reactions (placebo, 11·3 E/100PY; adalimumab, 5·3E/100PY). Serious 300 
infections occurred at a similar rate between groups. One malignancy (non-serious squamous cell 301 
carcinoma of skin) in the adalimumab group and 1 and 3 events of latent tuberculosis were 302 
reported in the placebo and adalimumab group, respectively. No active tuberculosis, lupus or 303 
lupus-like reaction or demyelinating disorders were reported. 304 
Seven patients (6·1%) in the placebo group and 10 patients (8·7%) in the adalimumab group 305 
discontinued study drug due to AEs. AEs leading to patient discontinuation in the adalimumab 306 
group included mycobacterium TB complex test positive (4 patients), pulmonary sarcoidosis (2 307 
patients), and bronchitis, neutropenia, hepatic stenosis, dermatitis, and worsened migraine (1 308 
patient each). Sixty patients were pseudophakic at baseline. Six (5.3%) patients in the placebo 309 
and 2 (1.7%) in the adalimumab groups, developed cataracts during the study. Overall, 2 patients 310 
in the placebo and 1 patient in the adalimumab group had cataract surgery/YAG-laser 311 
capsulotomy during the study, but continued in the study. AE results were consistent with the 312 
known safety profile of adalimumab across approved indications. One death due to aortic 313 
dissection and cardiac tamponade was reported post-treatment (Day 54 [18 days after last dose]) 314 
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in a patient randomised to adalimumab; the investigator considered the events not related to 315 
study drug (Table 3). Six patients (5·2%, n=6/115) had anti-adalimumab antibodies (AAA+) 316 
during the study. Five/six AAA+ patients experienced treatment failure at 13, 16, 16, 24 and 31 317 
weeks, respectively; median time to treatment failure was not estimable for AAA– patients, as 318 
more than half of the AAA– patients did not experience treatment failure (n=109). 319 
Discussion 320 
In the VISUAL II study, treatment of patients with inactive, non-infectious intermediate, 321 
posterior, or panuveitis with adalimumab significantly reduced the risk of treatment failure 322 
(uveitic flare or visual acuity loss),  as demonstrated by an early and sustained separation of 323 
adalimumab and placebo treatment failure curves. Median time to treatment failure for 324 
adalimumab-treated patients, although not estimable, was significantly longer than placebo. 325 
Patients receiving adalimumab met fewer treatment failure criteria as compared with the placebo 326 
group. The risk of treatment failure based on logMAR BCVA (visual acuity) was reduced by 327 
67% for patients in the adalimumab group compared to the placebo group. The rates of treatment 328 
failure based on active inflammatory lesions, AC cell grade and VH grade were numerically 329 
lower in the adalimumab group compared with placebo.   330 
Most of the measurable effect of adalimumab was on the BCVA component of the primary 331 
efficacy endpoint. Although the effect of adalimumab on the other inflammatory components of 332 
the primary endpoint was not significant, the improvement in BCVA is likely to be through its 333 
effect on multiple aspects of inflammation within the eye, some of which may not have been 334 
included in the multiple-component endpoint. The inflammatory manifestations observed in 335 
patients with vision loss that may have been, at least in part, the cause of the vision loss were 336 
increase in AC cell and VH grade (≥1), new inflammatory/chorioretinal vascular lesions, retinal 337 
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thickening, and cataracts. The cross-sectional study by Dick et al, based on population insurance 338 
data provides supportive evidence that the presence of chronic low grade inflammation in this 339 
group is associated with worse visual outcomes.2 340 
The efficacy results of this placebo-controlled trial were in accordance with previous studies. In 341 
VISUAL-I, a multicenter, double-masked controlled trial in patients with active non-infectious 342 
uveitis, adalimumab significantly reduced the risk of treatment failure by 50% compared to the 343 
placebo group.19 In both VISUAL-I (active disease) and VISUAL-II (inactive disease), the risk 344 
to fail was halved and the time to fail was nearly doubled. A retrospective study in patients with 345 
refractory chronic uveitis demonstrated that adalimumab effectively controlled inflammation in 346 
35% of patients refractory to previous treatment with infliximab or etanercept.23 In a prospective 347 
open-label pilot study of 19 patients with various uveitic diagnoses, adalimumab significantly 348 
reduced inflammation in 63% of patients with complete resolution of cystoid macular edema 349 
(CME) in 55% affected eyes after 1 year of treatment.24 In another non-comparative open-label 350 
prospective study of 31 patients with refractory uveitis, 68% of patients were clinical responders 351 
at 10 weeks, with sustained response at 50 weeks seen in 39% of the patients. 25 A multicenter 352 
prospective study of 131 patients with a mean age of 27 years also demonstrated that 353 
adalimumab therapy significantly improved anterior chamber and vitreous inflammation with the 354 
ability to taper CS.14 The French uveitis network recently published a multicenter observational 355 
study of 160 patients with refractory uveitis treated with anti-TNFα (infliximab and adalimumab) 356 
agents. The patients had an overall response rate of 93% at 12 months.26  357 
The low adalimumab immunogenicity observed in the current study was within the range of rates 358 
observed in other disease states.13 The safety profile of adalimumab in this study was comparable 359 
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to other approved indications. The rate of AEs, serious AEs and discontinuation due to an AE 360 
were similar in both adalimumab and placebo groups.13 No new safety signals were detected.27,28 361 
Previous clinical trials that were initiated to evaluate therapeutic potential for inactive, non-362 
infectious uveitis have either failed to achieve their primary endpoint or were prematurely 363 
terminated due to unknown reasons.29-31 Thus, VISUAL II is a first phase 3 trial of a nonsteroidal 364 
systemic medication in quiescent (inactive disease) patients to have reached its pre-specified 365 
primary endpoint (Time to treatment failure) and showed promise in treating inactive non-366 
infectious uveitis in patients dependent on chronic oral CS (≥10 mg/d) to maintain disease 367 
inactivity.  368 
The unique trial design, large study population, range of uveitis diagnoses and multiple 369 
component primary endpoint were strengths of this study. The composite primary endpoint 370 
assessed various facets of the disease, spanning from anterior to posterior segments of the eye, 371 
and facilitated detailed assessment of treatment response and efficacy since inflammation does 372 
not always manifest as a single endpoint such as VH. The CS-sparing effect of adalimumab 373 
could be assessed as all patients had a mandatory CS taper to zero. 374 
There were limitations to the interpretation of the secondary endpoints (change in AC cell grade, 375 
VH grade, and visual acuity) as the magnitude of the treatment effect was diluted because only a 376 
small percentage of patients had treatment failure due to 1 of the 4 components. Thus, the 377 
magnitude of mean change observed was small for these secondary endpoints. There could have 378 
been a “floor effect”, since most patients started with reasonably good visual acuity and minimal 379 
inflammation; it might have been difficult to detect a change particularly since more than half of 380 
the adalimumab group never achieved treatment failure. It is acknowledged that range of uveitis 381 
diagnoses, could also be recognised as a potential limitation since it does not provide us 382 
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information on which disease groups (with their recognised heterogeneity) are actually the 383 
responsive to the therapy. Due to difficulty in recruiting patients in a rare disease with multiple 384 
competing studies, no restriction on the number of recruiting sites was imposed, which we agree 385 
is a weakness of the study. In addition, the study was not statistically powered to analyze a 386 
differential efficacy among the different causes of uveitis. 387 
Studies or clinical trials intended for the treatment of uveitis face number of challenges. Uveitis 388 
is a heterogeneous group of conditions characterized by intraocular inflammation. Most uveitis 389 
syndromes are individually rare, but for taxonomic and clinical convenience are commonly 390 
clustered according to their anatomical classification, despite the wide range of systemic and 391 
clinical associations they represent. Another challenge that is encountered in any uveitis trial is 392 
the lack of high quality outcome measure. Currently, VH grade, as defined by Nussenblatt, is a 393 
disease activity surrogate endpoint that is accepted by the FDA for clinical trials. This score 394 
utilizes a subjective ordinal scale of cloudiness of the vitreous humor, but has significant inter-395 
observer variability. 396 
Treatment with adalimumab significantly lowered the risk for uveitic flare or visual acuity loss in 397 
patients with steroid-dependent inactive, non-infectious intermediate, posterior, or panuveitis. No 398 
new safety signals were identified with adalimumab treatment; the safety profile of adalimumab 399 
was comparable to other approved indications. The findings from this study suggest that 400 
adalimumab may be well tolerated and offers an effective treatment option for patients with 401 
inactive, non-infectious uveitis and/or who are at risk of the long-term side effects of CS. 402 
PANEL: RESEARCH IN CONTEXT Systematic Review: Evidence before this study 403 
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We searched PubMed for articles published up to March 20, 2016, in any language, for 404 
drugs/agents that have been used for the treatment of non-infectious uveitis and using the search 405 
terms: “non-infectious uveitis”, “anti-TNF”, “immunosuppression”, and “biologics”. There 406 
were numerous publications on the use of anti-TNF agents in the treatment of various types of 407 
anterior, intermediate, posterior or panuveitis. Several of these publications demonstrated the 408 
effectiveness of anti-TNF’s (infliximab and adalimumab) in the treatment of uveitis. It is well 409 
known that some of the diseases for which adalimumab is currently indicated, such as JIA, AS 410 
and PsA, can present with uveitis. There have been reports of efficacy of adalimumab in 411 
pediatric patients with JIA-associated or idiopathic uveitis. A retrospective study in patients with 412 
refractory chronic uveitis demonstrated that adalimumab effectively controlled inflammation in 413 
35% of patients refractory to previous treatment with infliximab or etanercept. In a prospective 414 
open-label pilot study of 19 patients with various uveitic diagnoses, adalimumab significantly 415 
reduced inflammation in 63% of patients with complete resolution of cystoid macular edema 416 
(CME) in 55% of eyes after 1 year of treatment. A multicenter study of 131 patients with a mean 417 
age of 27 years also demonstrated that adalimumab therapy significantly improved anterior 418 
chamber and vitreous inflammation with the ability to taper CS. In an open-label study of 419 
infliximab, 77% patients with refractory autoimmune uveitis achieved clinical success by week 420 
10. In the open-label uncontrolled RHAPSODY study in AS patients, adalimumab decreased the 421 
rate of acute anterior uveitis flares by 51%. In a prospective study, adalimumab reduced 422 
anterior chamber and vitreous inflammation, improved visual acuity and reduced the 423 
corticosteroid burden in patients with refractory uveitis. The French uveitis network recently 424 
published a multicenter study of 160 patients with refractory uveitis treated with anti-TNFα 425 
(infliximab and adalimumab) agents. The patients had an overall response rate of 93% at 12 426 
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months. However, most of these are case reports/series or open-label studies. An adequate, well-427 
controlled study of the efficacy and safety of anti-TNF therapy is lacking in the current 428 
literature.  Previous clinical trials that were initiated to evaluate therapeutic potential for 429 
inactive, non-infectious uveitis have either failed to achieve their primary endpoint or were 430 
prematurely terminated due to unknown reasons.  431 
Added value of this study 432 
VISUAL-II is a multinational Phase 3, randomised, double-masked, study assessing the efficacy 433 
and safety of adalimumab in patients with inactive non-infectious intermediate, posterior, or 434 
panuveitis requiring corticosteroids. This study was done in 21 countries involving 62 study 435 
sites, representative of the global diversity of the study population. This is the first study to have 436 
achieved its pre-specified primary endpoint (Time to treatment failure) and showed promise in 437 
treating inactive non-infectious uveitis in patients dependent on chronic oral CS (≥10 mg/d) to 438 
maintain disease inactivity. The safety profile was consistent with the known safety profile of 439 
adalimumab across approved indications. 440 
Interpretation: Implications of all the available evidence 441 
Results from this study indicate that treatment with adalimumab significantly lowered the risk for 442 
uveitic flare or visual acuity loss in patients with steroid-dependent inactive, non-infectious 443 
intermediate, posterior, or panuveitis. No new safety signals were identified with adalimumab 444 
treatment; the safety profile of adalimumab was comparable to other approved indications. The 445 
findings from this study suggest that adalimumab may be well tolerated and offers an effective 446 
treatment option for patients with inactive, non-infectious uveitis and/or who are at risk of the 447 
long-term side effects of CS. 448 
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Figure legends 620 
Figure 1. Trial Profile 621 
 622 
Figure 2. Treatment failure rate (Kaplan-Meier curve). (A) Treatment failure because of any reason, and (B) 623 
treatment failure rate due to vitreous haze, new lesions, anterior chamber cells, and best corrected visual acuity. 624 
HR=hazard ratio. 625 
 626 
Figure 3. Causes of treatment failure. (A) Number of reasons for treatment failure per treatment group; (B) 627 
individual reasons for treatment failure per treatment group. Percentages of patients are indicated above the bars. 628 
TF=treatment failure. 629 
 630 
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Table 1. Patient Demographic and Baseline Characteristics (Intent-to-Treat Population) 651 
 Placebo 
(n=111) 
Adalimumab 
(n=115) 
Sex, n (%)   
   Female 72 (64·9) 66 (57·4) 
Race, n (%)   
   White 93 (83·8) 96 (83·5) 
   Black or African American 8 (7·2) 6 (5·2) 
   Asian 3 (2·7) 3 (2·6) 
   Other 5 (4·5) 9 (7·8) 
   Age, years   
   Mean ± SD 42·2±14·0 42·9±12·9 
   Range 20-79 18-75 
Type of Uveitis, n (%)   
   Intermediate 30 (27·0) 17 (14·8) 
   Posterior 34 (30·6) 39 (33·9) 
   Panuveitis 46 (41·4) 57 (49·6) 
   Intermediate/Posterior 1 (0·9) 2 (1·7) 
Diagnosis, n (%)   
   Idiopathic 40 (36·0) 29 (25·2) 
   Birdshot Choroidopathy 15 (13·5) 15 (13·0) 
   Multifocal Choroiditis & panuveitis 2 (1·8) 5 (4·3) 
   Vogt Koyanagi Harada 25 (22·5) 26 (22·6) 
   Sarcoid 14 (12·6) 18 (15·7) 
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 658 
   Behçet’s 6 (5·4) 10 (8·7) 
   Other 9 (8·1) 12 (10·4) 
Affected Eye, n (%)   
   Left 3 (2·7) 2 (1·7) 
   Right 4 (3·6) 1 (0·9) 
   Both 104 (93·7) 112 (97·4) 
Duration of Uveitis, months   
   Mean ± SD 62·9±67·7 59·5±64·5 
   Range 4-394 2-381 
No. of flares in past 12 months, n (%)   
   0-1 46 (41·4) 48 (41·7) 
    2 40 (36·0) 43 (37·4) 
    ≥3 25 (22·5) 24 (20·9) 
Concomitant Immunomodulators at baseline, n (%)   
Azathioprine 11 (9·9) 3 (2·6) 
Cyclosporine 11 (9·9) 15 (13·0) 
Methotrexate 14 (12·6) 19 (16·5) 
Mycophenolate mofetil 17 (15·3) 17 (14·8) 
Tacrolimus 0 0 
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Table 2.  Summary of Ranked Secondary Efficacy Variables (ITT population) 659 
Ranked Secondary Variable* 
 
Placebo 
(n=111) 
Adalimumab  
(n=115) P 
Value na Mean na Mean 
1.  Change in AC cell grade       
 Left eye 110 0·57 115 0·41 
 Right eye 110 0·53 115 0·40 
Difference, mean (95% CI) -0·14 (-0·37, 0·08) 0·218b 
   
2.  Change in VH       
 Left eye 110 0·33 115 0·16 
 Right eye 110 0·27 115 0·18 
Difference, mean (95% CI) -0·13 (-0·28, 0·01) 0·070b 
   
3.  Change in logMAR BCVA      
 Left eye 110 0·06 115 0·01 
 Right eye 110 0·02 115 -0·01 
Difference, mean (95% CI) -0·04 (-0·08, 0·01) 0·096b 
   
4.  Time to OCT evidence of ME (months) on or 
after Week 2  
        Median 
 
95 
 
NE 
 
90 
 
NE 
 
Hazard ratio (95% CI) 0·75 (0·34, 1·69)c 0·491f 
 
5.  Percent change in central retinal thickness       
 Left eye 107 6·4 114 4·5 
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 Right eye 108 7·7 113 5·4 
Difference, mean (95% CI) -2·3 (-8·5, 3·8) 0·451d 
   
6.  Change in VFQ-25 total score  109 1·24 115 3·36  
Difference, mean (95% CI) 2·12 (-0·84, 5·08) 0·16e 
   
7.  Change in VFQ-25 distance vision subscore 109 0·76 115 2·64  
Difference, mean (95% CI) 1·88 (-2·53, 6·29) 0·40e 
 
8.  Change in VFQ-25 near vision subscore 109 3·98 115 3·88  
Difference, mean (95% CI) -0·10 (-4·81, 4·61) 0·97e 
 
9.  Change in VFQ-25 ocular pain subscore  109 2·87 115 3·42  
Difference, mean (95% CI) 0·56 (-4·56, 5·68) 0·83e 
AC=anterior chamber; BCVA=best-corrected visual acuity; ME=macular edema; OCT=optical coherence 
tomography; VFQ-25=Visual Functioning Questionnaire-25; VH=vitreous haze. 
*With the exception of endpoint 4 (time to OCT evidence of ME), data reflect change from BL to final or early 
termination visit 
a. For each endpoint, n = number of patients with non-missing value. 
b. From ANOVA of change from BL to the final/early termination visit with treatment as factor adjusted for 
clustered observations.  
c. HR of adalimumab vs placebo from proportional hazards regression with treatment as factor. 
d.    From ANOVA of change from BL to the final/early termination visit with treatment and type of OCT machine 
as factors adjusted for clustered observations     
e. From ANOVA of change from BL to the final/early termination visit with treatment as factor. 
f.     Log rank test. 
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Table 3.  Adverse Events (Safety Population) 662 
AEs, Events (Events per 100PY) 
Placebo 
(N=114, PYs=71·0) 
Adalimumab 
(N=115, PYs=94·5) 
Any AE 642 (905) 831 (879) 
AE leading to death* 0 2 (2·1) 
Serious AE 10 (14·1) 13 (13·8) 
AE leading to discontinuation of 
adalimumab/placebo 7 (9·9) 11 (11·6) 
Serious infectious AE 2 (2·8) 3 (3·2) 
Injection site reactions 16 (22·6) 36 (38·1) 
Malignancies† 0 1 (1·1) 
Opportunistic infections (excluding oral 
candidiasis and TB) 0 0 
Active tuberculosis 0 0 
Latent tuberculosis 1 (1·4) 3 (3·2) 
Demyelinating disease 0 0 
Lupus-like reaction 0 0 
Allergic reactions (including angioedema, 
anaphylaxis) 8 (11·3) 5 (5·3) 
*One death, due to2 fatal AEs of aortic dissection and cardiac tamponade (18 days after last ADA dose), not related 663 
to ADA treatment. †One event of non-serious squamous cell carcinoma of skin (day 210; resolved on day 215; ADA 664 
treatment was not interrupted). 665 
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